Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1186/s40425-018-0342-x http://scihub22266oqcxt.onion/10.1186/s40425-018-0342-x C5950135!5950135!29754585     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Immunother+Cancer 2018 ; 6 (ä): ä Nephropedia Template TP {{tp|p=29754585|t=2018. Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease |pdf=|usr=}}{{29754585}} gab.com Text Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease JO: J Immunother Cancer http://www.kidney.de/pget.php?&tw=1&pmid=29754585 #FOAvip The U.S. Food and Drug Administration (FDA) recently approved pembrolizumab, an anti- programmed cell death protein 1 cancer immunotherapeutic, for use in advanced solid tumors in patients with the microsatellite-high/DNA mismatch repair-deficient biomarker. This is the first example of a tissue-agnostic FDA approval of a treatment based on a patient?s tumor biomarker status, rather than on tumor histology. Here we discuss key issues and implications arising from the biomarker-based disease classification implied by this historic approval. Twit Text FOAVip Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease ????J Immunother Cancer http://www.kidney.de/pget.php?&tw=1&pmid=29754585 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=29754585 #FOAvip English Wikipedia <ref>{{Cite pmid|29754585}}</ref> Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease #MMPMID29754585 Boyiadzis MM; Kirkwood JM; Marshall JL; Pritchard CC; Azad NS; Gulley JL J Immunother Cancer 2018[]; 6 (ä): ä PMID29754585show ga The U.S. Food and Drug Administration (FDA) recently approved pembrolizumab, an anti- programmed cell death protein 1 cancer immunotherapeutic, for use in advanced solid tumors in patients with the microsatellite-high/DNA mismatch repair-deficient biomarker. This is the first example of a tissue-agnostic FDA approval of a treatment based on a patient?s tumor biomarker status, rather than on tumor histology. Here we discuss key issues and implications arising from the biomarker-based disease classification implied by this historic approval. äSignificance and implications of FDA approval of pembrolizumab for bio(epmc).pdf DeepDyve Pubget Overpricing